If this theory is confirmed, β3-AR agonists might enhance organ vascularization and maturation, thereby helping to prevent intestinal diseases such as NEC, in which premature exposure to a hyperoxic environment disrupts vascularization and normal tissue development, increasing the risk of hypoxic-ischemic injury [29]. The gene discussed is ADRB3; the disease is intestinal disorder.